-
Overview of Tumefactive Multiple Sclerosis
30 Apr 2024 21:12 GMT
… doctor may prescribe other medications, such as:
the biological medication rituximab
the chemotherapy drug cyclophosphamide … is considered tumefactive multiple sclerosis?
Tumefactive MS … risk of brain cancer. However, … cure, but medical treatment can help you …
-
Smart Immune treats adult acute leukemia patient at final dose level in Phase I/II ReSET-02 trial
02 May 2024 10:00 GMT
… cancers and infections, today announces the treatment … cyclophosphamide (PTCy), in adult patients with acute lymphoid leukemia. The trial … Medicines Agency and the US Food and Drug Administration (FDA … a clinical-stage biotechnology company developing ProTcell …
-
Replay wins IND clearance for PRAME T cell cancer therapy
01 May 2024 16:11 GMT
… Food and Drug Administration (FDA) to initiate a clinical trial of … Standard doses of fludarabine/cyclophosphamide (Flu/Cy) and … target for cell therapy-mediated cancer immunotherapy. In February 2024 … as a first-line treatment for melanoma.
At the …
-
National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma
01 May 2024 11:29 GMT
… with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and … conducting multiple clinical trials in China and … trial of the first-line treatment of non-small cell lung cancer … Medicine
About Chipscreen
Chipscreen Biosciences is an innovative drug …
-
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
01 May 2024 11:26 GMT
… S. Food and Drug Administration (FDA) under accelerated … trials studying KEYTRUDA across a wide variety of cancers and treatment … cyclophosphamide) followed by surgery and continued adjuvant treatment … development of important medicines and vaccines. We aspire …
-
Replay and MD Anderson announce FDA clearance of IND application for first-in-class PRAME-targeted T-Cell Receptor Natural Killer (TCR-NK) cell therapy for hematological malignancies
30 Apr 2024 11:00 GMT
… Cancer Center, today announced that the Food & Drug Administration (FDA … on numerous different cancer types, including hematologic … doses of fludarabine/cyclophosphamide (Flu/Cy) … cancer patients with high unmet medical needs and limited treatment …
-
MD Anderson and Replay announce FDA clearance of IND application for first-in-class PRAME-targeted TCR NK cell therapy for hematological malignancies
30 Apr 2024 11:12 GMT
… Cancer Center and Replay today announced that the Food & Drug Administration (FDA … 47;cyclophosphamide (Flu … cancer patients with high unmet medical needs and limited treatment options.”
“The recent FDA … Cancer Institute (NCI)-designated comprehensive cancer …
-
AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
03 May 2024 01:30 GMT
… U.S. Food and Drug Administration (FDA) review of the … de novo or treatment-emergent neuroendocrine prostate cancer, is ongoing. … Medicines Agency (EMA) of the CodeBreaK 200 Phase 3 trial … with Rituximab or a cyclophosphamide-containing regimen in children …
-
HSCT Post-Myeloablation Leads to Longterm Normalization of SSc Molecular Signatures
01 May 2024 00:52 GMT
… et al.
In Scleroderma: Cyclophosphamide or Transplantation trial (SCOT), when myeloablation was … either HSCT or received intravenous cyclophosphamide (CYC) for 12 months.
They …
-
Novel tool helps predict risk for heart complications after bone marrow transplant
04 May 2024 10:21 GMT
… transplantation, when high-dose cyclophosphamide and total body irradiation … adjunct professor of internal medicine-cardiology at University of … Michigan Medical School, told Healio. … and implement in electronic medical records.
Healio: How …